---
title: "Humanwell Healthcare Subsidiary Gets Clinical Trial Approval for Schizophrenia Medication"
date: "2025-02-11 10:45:17"
summary: "Humanwell Healthcare  subsidiary Yichang Renfu obtained approval from China's drug administrator to conduct clinical trials for brepirazoline tablets. The drug is used for the treatment of adult schizophrenia and as an adjunctive therapy for depression, according to a Tuesday filing with the Shanghai bourse."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Humanwell Healthcare subsidiary Yichang Renfu obtained approval from China's drug administrator to conduct clinical trials for brepirazoline tablets.

The drug is used for the treatment of adult schizophrenia and as an adjunctive therapy for depression, according to a Tuesday filing with the Shanghai bourse.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:G2465955:0/)
